SuperworthInsight Molecular Diagnostics market cap IMDX
Share price times shares outstanding: what the whole company sells for, since 2016.
- Today, Oct 23, 2026
- $92.6M
- Highest close in our data
- $529.1M
- Jul 2021
Insight Molecular Diagnostics is worth $92.6M at the close on Oct 23, 2026, at $2.83 a share.
That is down 51% over the last year and down 69% over five years.
Its highest close in our data was $529.1M in Jul 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $92.6M | $92.6M | $213.3M | −49% |
| 2025 | $182.6M | $33.8M | $212.1M | +414% |
| 2024 | $35.5M | $20.5M | $45.6M | +72% |
| 2023 | $20.7M | $18.8M | $57.9M | −46% |
| 2022 | $38.1M | $37M | $190M | −81% |
| 2021 | $200.1M | $199.2M | $529.1M | +25% |
| 2020 | $160.7M | $83.4M | $226.5M | +46% |
| 2019 | $110.2M | $65.1M | $283.3M | +84% |
| 2018 | $59.8M | $42.4M | $138.3M | −59% |
| 2017 | $146.1M | $105.7M | $236.6M | −28% |
| 2016 | $202.4M | $87.7M | $221.1M | n/a |
Against its peers
Companies in Healthcare nearest Insight Molecular Diagnostics' size, closest first, today.
| Company | Market cap |
|---|---|
| IMDXInsight Molecular Diagnostics | $92.6M |
| ICCCImmucell | $93.1M |
| KEQUKewaunee Scientific | $94.9M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| APTAlpha Pro Tech | $56.7M |
| ATNMActinium Pharmaceuticals | $47.8M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| ELMDElectromed | $220.6M |
| Peer median | $94M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Insight Molecular Diagnostics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.